Vaccination with CTL epitopes that escape

An alternative approach to HIV vaccine development?

David O'Connor, Todd Allen, David Watkins

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This article describes a novel approach to HIV vaccine design that is, as yet, unproven and still in preliminary development. In rhesus macaques infected with simian immunodeficiency virus (SIV), we have identified particular cellular immune responses that select for viral variants during primary infection. We speculate that the detection of viral variants with altered amino acids in CTL epitopes implies the successful clearance of cells harboring wild-type virus. Here, we present our rationale suggesting why such potent early CTL responses that exert an antiviral effect may be particularly attractive targets for induction by candidate vaccines. Conventional wisdom suggests that regions of the virus that are structurally and functionally important will generally be well-conserved both among clades and within an infected host. Amino acid replacements within these well-conserved regions should be difficult for the virus to accommodate. Therefore, these regions are traditionally considered ideal targets for vaccine induced immune responses because they are refractory to CTL escape mutations. Many examples of these regions have been identified in both HIV-1 and SIVmac (J. Immunol. 162 (1999) 3727; J. Virol. 67 (1993) 438) and have been included in candidate vaccine formulations. Human clinical trials testing these vaccines are currently underway. Our proposed method of vaccination with CTL epitopes that escape explores an alternative hypothesis. Rather than engendering responses to regions of the virus that do not escape, we reason that vaccination needs to accelerate the development of the initial immune responses that effectively select for amino acid variants during acute infection. By examining CTL escape during the acute phase, we will identify CTL responses that the virus cannot tolerate and incorporate these responses into vaccines.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalImmunology Letters
Volume79
Issue number1-2
DOIs
StatePublished - Nov 1 2001
Externally publishedYes

Fingerprint

AIDS Vaccines
Epitopes
Vaccination
Vaccines
Viruses
Amino Acids
Simian Immunodeficiency Virus
Infection
Macaca mulatta
Cellular Immunity
Antiviral Agents
HIV-1
Clinical Trials
Mutation

Keywords

  • CTL
  • Escape
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Vaccination with CTL epitopes that escape : An alternative approach to HIV vaccine development? / O'Connor, David; Allen, Todd; Watkins, David.

In: Immunology Letters, Vol. 79, No. 1-2, 01.11.2001, p. 77-84.

Research output: Contribution to journalArticle

@article{b69d2c08778343bbb1f1435ee05636b7,
title = "Vaccination with CTL epitopes that escape: An alternative approach to HIV vaccine development?",
abstract = "This article describes a novel approach to HIV vaccine design that is, as yet, unproven and still in preliminary development. In rhesus macaques infected with simian immunodeficiency virus (SIV), we have identified particular cellular immune responses that select for viral variants during primary infection. We speculate that the detection of viral variants with altered amino acids in CTL epitopes implies the successful clearance of cells harboring wild-type virus. Here, we present our rationale suggesting why such potent early CTL responses that exert an antiviral effect may be particularly attractive targets for induction by candidate vaccines. Conventional wisdom suggests that regions of the virus that are structurally and functionally important will generally be well-conserved both among clades and within an infected host. Amino acid replacements within these well-conserved regions should be difficult for the virus to accommodate. Therefore, these regions are traditionally considered ideal targets for vaccine induced immune responses because they are refractory to CTL escape mutations. Many examples of these regions have been identified in both HIV-1 and SIVmac (J. Immunol. 162 (1999) 3727; J. Virol. 67 (1993) 438) and have been included in candidate vaccine formulations. Human clinical trials testing these vaccines are currently underway. Our proposed method of vaccination with CTL epitopes that escape explores an alternative hypothesis. Rather than engendering responses to regions of the virus that do not escape, we reason that vaccination needs to accelerate the development of the initial immune responses that effectively select for amino acid variants during acute infection. By examining CTL escape during the acute phase, we will identify CTL responses that the virus cannot tolerate and incorporate these responses into vaccines.",
keywords = "CTL, Escape, Vaccine",
author = "David O'Connor and Todd Allen and David Watkins",
year = "2001",
month = "11",
day = "1",
doi = "10.1016/S0165-2478(01)00268-1",
language = "English",
volume = "79",
pages = "77--84",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Vaccination with CTL epitopes that escape

T2 - An alternative approach to HIV vaccine development?

AU - O'Connor, David

AU - Allen, Todd

AU - Watkins, David

PY - 2001/11/1

Y1 - 2001/11/1

N2 - This article describes a novel approach to HIV vaccine design that is, as yet, unproven and still in preliminary development. In rhesus macaques infected with simian immunodeficiency virus (SIV), we have identified particular cellular immune responses that select for viral variants during primary infection. We speculate that the detection of viral variants with altered amino acids in CTL epitopes implies the successful clearance of cells harboring wild-type virus. Here, we present our rationale suggesting why such potent early CTL responses that exert an antiviral effect may be particularly attractive targets for induction by candidate vaccines. Conventional wisdom suggests that regions of the virus that are structurally and functionally important will generally be well-conserved both among clades and within an infected host. Amino acid replacements within these well-conserved regions should be difficult for the virus to accommodate. Therefore, these regions are traditionally considered ideal targets for vaccine induced immune responses because they are refractory to CTL escape mutations. Many examples of these regions have been identified in both HIV-1 and SIVmac (J. Immunol. 162 (1999) 3727; J. Virol. 67 (1993) 438) and have been included in candidate vaccine formulations. Human clinical trials testing these vaccines are currently underway. Our proposed method of vaccination with CTL epitopes that escape explores an alternative hypothesis. Rather than engendering responses to regions of the virus that do not escape, we reason that vaccination needs to accelerate the development of the initial immune responses that effectively select for amino acid variants during acute infection. By examining CTL escape during the acute phase, we will identify CTL responses that the virus cannot tolerate and incorporate these responses into vaccines.

AB - This article describes a novel approach to HIV vaccine design that is, as yet, unproven and still in preliminary development. In rhesus macaques infected with simian immunodeficiency virus (SIV), we have identified particular cellular immune responses that select for viral variants during primary infection. We speculate that the detection of viral variants with altered amino acids in CTL epitopes implies the successful clearance of cells harboring wild-type virus. Here, we present our rationale suggesting why such potent early CTL responses that exert an antiviral effect may be particularly attractive targets for induction by candidate vaccines. Conventional wisdom suggests that regions of the virus that are structurally and functionally important will generally be well-conserved both among clades and within an infected host. Amino acid replacements within these well-conserved regions should be difficult for the virus to accommodate. Therefore, these regions are traditionally considered ideal targets for vaccine induced immune responses because they are refractory to CTL escape mutations. Many examples of these regions have been identified in both HIV-1 and SIVmac (J. Immunol. 162 (1999) 3727; J. Virol. 67 (1993) 438) and have been included in candidate vaccine formulations. Human clinical trials testing these vaccines are currently underway. Our proposed method of vaccination with CTL epitopes that escape explores an alternative hypothesis. Rather than engendering responses to regions of the virus that do not escape, we reason that vaccination needs to accelerate the development of the initial immune responses that effectively select for amino acid variants during acute infection. By examining CTL escape during the acute phase, we will identify CTL responses that the virus cannot tolerate and incorporate these responses into vaccines.

KW - CTL

KW - Escape

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0035501137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035501137&partnerID=8YFLogxK

U2 - 10.1016/S0165-2478(01)00268-1

DO - 10.1016/S0165-2478(01)00268-1

M3 - Article

VL - 79

SP - 77

EP - 84

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

IS - 1-2

ER -